Notably, the only trial targeting NF‐κB in MDS patients has focused on low‐risk patients [33], which may account for their only moderate outcomes, as the induction of apoptosis may have greater effects on anti‐apoptotic phenotypes [30]. Here, NFKB1 is linked to myelodysplastic syndrome.